Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
Hashem Abu SerhanMohammad J J TahaMohammad T AbuawwadAbdelaziz AbdelaalSara IrshaidatLeen Abu SerhanQusai Faisal Abu SalimNour AwamlehBasel AbdelazeemAyman G ElnahryPublished in: Seminars in ophthalmology (2023)
Brolucizumab is a new drug that has potential advantages in efficacy over other anti-VEGF agents in the treatment of DME and DR. It showed significant improvement in BCVA and CSMT with the possibility of a lower dosing schedule compared to other agents. Although observed in low frequency, sight-threatening adverse effects appear to occur more frequently compared to other anti-VEGF agents. The main observed adverse event was retinal vasculitis which was seen more commonly with the 3 mg dose versus the 6 mg dose.